Literature DB >> 21707310

Tuberculosis drugs: new candidates and how to find more.

Claudia Sala1, Ruben C Hartkoorn.   

Abstract

The recent years have witnessed significant progress in the development of new drug candidates for the treatment of TB. While many of these are now in clinical trials, continued research is needed in order to sustain the drug discovery pipeline and meet the increasing needs of TB patients. These include shortening treatment, killing drug-resistant strains, and finding medications compatible with antiretroviral and diabetes therapy. Nowadays, TB drug discovery benefits from high-throughput screening methods, availability of conditional expression systems, and biophysical and biochemical techniques that enable target-based rational drug design. This article reviews the current state of TB drug development and discusses possible approaches to finding new leads.
© 2011 Future Medicine Ltd

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707310     DOI: 10.2217/fmb.11.46

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  15 in total

Review 1.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

2.  Functional analyses of mycobacterial lipoprotein diacylglyceryl transferase and comparative secretome analysis of a mycobacterial lgt mutant.

Authors:  Andreas Tschumi; Thomas Grau; Dirk Albrecht; Mandana Rezwan; Haike Antelmann; Peter Sander
Journal:  J Bacteriol       Date:  2012-05-18       Impact factor: 3.490

3.  Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.

Authors:  Wei Li; Ashutosh Upadhyay; Fabio L Fontes; E Jeffrey North; Yuehong Wang; Debbie C Crans; Anna E Grzegorzewicz; Victoria Jones; Scott G Franzblau; Richard E Lee; Dean C Crick; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

Review 4.  Learning from the past for TB drug discovery in the future.

Authors:  Katarína Mikušová; Sean Ekins
Journal:  Drug Discov Today       Date:  2016-10-04       Impact factor: 7.851

5.  Mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis.

Authors:  Ruben C Hartkoorn; Olga B Ryabova; Laurent R Chiarelli; Giovanna Riccardi; Vadim Makarov; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.

Authors:  Benoit Lechartier; Ruben C Hartkoorn; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

7.  Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.

Authors:  Wei Li; Andrés Obregón-Henao; Joshua B Wallach; E Jeffrey North; Richard E Lee; Mercedes Gonzalez-Juarrero; Dirk Schnappinger; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 8.  Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.

Authors:  Mary Jackson; Michael R McNeil; Patrick J Brennan
Journal:  Future Microbiol       Date:  2013-07       Impact factor: 3.165

9.  Recent developments in the epidemiology and management of tuberculosis - new solutions to old problems?

Authors:  Wolfgang M Thaiss; Cornelius C Thaiss; Christoph A Thaiss
Journal:  Infect Drug Resist       Date:  2012-01-09       Impact factor: 4.003

Review 10.  Tuberculosis drug discovery in the post-post-genomic era.

Authors:  Benoit Lechartier; Jan Rybniker; Alimuddin Zumla; Stewart T Cole
Journal:  EMBO Mol Med       Date:  2014-01-08       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.